sorafenib tosylate + everolimus
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acinar Cell Adenocarcinoma of the Pancreas
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Trial Timeline
Aug 1, 2009 → Dec 1, 2012
NCT ID
NCT00981162About sorafenib tosylate + everolimus
sorafenib tosylate + everolimus is a phase 1 stage product being developed by Bayer for Acinar Cell Adenocarcinoma of the Pancreas. The current trial status is completed. This product is registered under clinical trial identifier NCT00981162. Target conditions include Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00981162 | Phase 1 | Completed |